Stryker Corporation (NYSE:SYK) Director Howard E. Cox, Jr. sold 7,400 shares of Stryker stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $164.09, for a total transaction of $1,214,266.00. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Stryker Corporation (NYSE SYK) traded up $1.01 during trading hours on Thursday, reaching $157.25. The company’s stock had a trading volume of 139,872 shares, compared to its average volume of 1,438,987. The company has a current ratio of 2.29, a quick ratio of 1.59 and a debt-to-equity ratio of 0.66. Stryker Corporation has a 52 week low of $124.89 and a 52 week high of $170.00. The stock has a market cap of $57,904.67, a PE ratio of 58.30, a PEG ratio of 2.22 and a beta of 0.70.
Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.01. The company had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.78 EPS. sell-side analysts forecast that Stryker Corporation will post 7.12 EPS for the current year.
Several brokerages have commented on SYK. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research report on Wednesday, January 31st. Oppenheimer reiterated a “hold” rating and issued a $165.00 price target on shares of Stryker in a research report on Thursday, February 1st. Piper Jaffray Companies reiterated a “buy” rating and issued a $170.00 price target on shares of Stryker in a research report on Wednesday, January 31st. Cantor Fitzgerald reiterated a “hold” rating and issued a $163.00 price target on shares of Stryker in a research report on Tuesday, January 30th. Finally, Barclays boosted their price objective on Stryker from $137.00 to $148.00 and gave the stock an “underweight” rating in a report on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $162.50.
Several hedge funds and other institutional investors have recently made changes to their positions in SYK. Truewealth LLC bought a new stake in shares of Stryker in the 4th quarter valued at approximately $110,000. Acrospire Investment Management LLC bought a new stake in shares of Stryker in the 2nd quarter valued at approximately $111,000. Sawyer & Company Inc bought a new stake in shares of Stryker in the 4th quarter valued at approximately $125,000. Sit Investment Associates Inc. grew its stake in shares of Stryker by 114.3% in the 4th quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after buying an additional 440 shares in the last quarter. Finally, Virtue Capital Management LLC bought a new stake in shares of Stryker in the 4th quarter valued at approximately $133,000. 74.71% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was first posted by Week Herald and is owned by of Week Herald. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://weekherald.com/2018/02/15/stryker-corporation-syk-director-sells-1214266-00-in-stock.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.